TIDMKING 
 
THE DIRECTORS OF IGRAINE PLC CONSIDER THIS ANNOUNCEMENT TO CONTAIN INSIDE 
INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO. 594/2014 OF 
THE EUROPEAN PARLIAMENT AND THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE AS IT 
FORMS PART OF RETAINED EU LAW AS DEFINED IN THE EUROPEAN UNION (WITHDRAWAL) ACT 
2018. BY PUBLICATION OF THIS ANNOUNCEMENT, THE INFORMATION SET OUT WITHIN IT IS 
DEEMED NOW TO BE IN THE PUBLIC DOMAIN. 
 
22 December 2021 
 
                                  Igraine Plc 
 
                         ("Igraine" or "the Company") 
 
               Interim Results for the Half-Year to 30 June 2021 
 
Igraine plc, Directors Statement, 
 
I am pleased to present the interim results for Igraine plc (AQSE: KING) for 
the period ending 30 June 2021 which has represented a transitionary period 
that has proved intense, productive, and exciting. The financial statements 
below have been approved by the Board of Directors and have not been reviewed 
by the company's auditors. 
 
Corporate Highlights from the Period: 
 
In April 2021, incoming Directors, Burns Singh Tennent-Bhohi and Simon 
Grant-Rennick led a recapitalisation and restructure exercise resulting in the 
lifting of the shares suspension, enabling the company to progress and develop 
a revitalised investment policy and business model. 
 
Importance was placed on identifying an investment sector for which the Board 
felt offered optionality in investment approach, would attract strong levels of 
capital interest and would be supported by professionals with a track-record of 
success within the chosen sector. 
 
Following internal discussions, review, and meetings with our advisors, on 11 
June 2021 the Board posted a circular and Notice of General Meeting to the 
shareholders of the company to put forward proposals including to adopt an 
investment strategy that would form the framework for what is now, Igraine plc. 
 
The proposals put to the shareholders were centred around forming a 
Co-Investment Agreement with Excalibur Healthcare Services ("EHS"), a company 
founded by the renowned scientist and highly successful entrepreneur, Professor 
Sir Christopher Evans. Over the last 30 years Professor Sir Christopher Evans 
has built more than 50 medical companies from start-up and floated 20 new 
medical businesses on stock markets in six different countries. He has created 
11 successful academic spin-outs and companies worth over $2.4 billion, and has 
raised $2.6 billion from disposals. He directed the raising of approximately 
$450 million for Merlin Biosciences Funds and $2.6 billion from disposals 
including the sale of BioVex Group, Inc. to Amgen Inc. and Piramed Limited to 
Roche Group. Through Merlin Ventures Limited, he co-founded and advised Biotech 
Growth Trust plc. Arakis Limited, one of the companies developed by Chris Evans 
was sold to Sosei Co. Ltd for $187 million. Chris Evans has founded notable 
companies such as Chiroscience, Celsis, ReNeuron, Vectura, Biovex and Merlin 
Biosciences Ltd. Appointed an OBE in 1995 for services to medical bioscience he 
was knighted in 2001 for services to bioscience and enterprise. Latterly he was 
founder of Arix Bioscience plc (LSE:ARX), of the oncology specialist Ellipses 
Pharma Limited and of Excalibur Healthcare Services Ltd. 
 
Included within the Circular put to the shareholders was the: 
 
  * The conditionally brokered financing, led by Peterhouse Capital, raising 
    gross proceeds before expenses of, £2,000,500 
  * The appointment of Peterhouse Capital as Corporate Advisor and Corporate 
    Broker to the company 
  * The Co-Investment Rights with Excalibur Healthcare 
  * The acquisition of a 2% stake in Excalibur Medicines Ltd ("EML") 
  * The appointment to the Board of Directors of, Professor Sir Christopher 
    Evans (Executive Chairman), Martin Walton (Executive Director) & Steven 
    Winfield (Executive Director) resulting in Simon Grant-Rennick and Burns 
    Singh Tennent-Bhohi both becoming Non-Executive Directors of the company 
  * The adoption of a new investment policy to reflect med-tech and life 
    sciences 
  * The change of name and ticker of the company to Igraine plc and AQSE: KING, 
    respectively 
  * A share consolidation and sub-division of the company's share capital 
 
The resolutions and proposals put to shareholders were all passed on the 28 
June 2021. 
 
Igraine plc is now a well-capitalised company with a sense of purpose and 
direction supported by one of the most successful biotech and life sciences 
entrepreneurs in the world. The company has completed its first investment 
under the Co-Investment Agreement with Excalibur Healthcare Services ("EHS") 
through the acquisition of a 2% interest in Excalibur Medicines Ltd ("EML"), a 
company that has secured exclusive rights to and owns the patents on a drug, 
AZD1656, which is being developed as a potential therapeutic for people with 
diabetes suffering from COVID-19. Due to there are very few new therapeutics in 
development for COVID-19 and associated virally transmitted diseases (most 
research is in combining existing treatments) this has the potential to be 
highly attractive to big pharma and biotech buyers. 
 
The company was suspended in September of this year due to failure to submit 
the financial statements to the year-end 30 December 2020. The Board wish to 
thank shareholders for their patience and understanding during this period. 
Recapitalisation and restructuring exercises are not without complications and 
the Board wish to reassure shareholders that adequate internal protocols and 
reporting functions are in place to ensure the company operates efficiently 
post this corporate restructure. 
 
On behalf of the Board 
 
Burns Singh Tennent-Bhohi 
 
Non-Executive Director 
 
 
 
 
 
 
 
 
 
 
INTERIM INCOME STATEMENT (UNAUDITED) 
 
For the period ended 30 June 2021 
 
                                                                Igraine plc 
 
                                                      6 mths to               6 mths to 
 
                                                        30 June                 30 June 
 
                                                           2021                    2020 
 
                                                          £ GBP                   £ GBP 
 
Revenue                                                       0                       0 
 
Cost of Sales                                                 0                       0 
 
Gross Profit/(Loss)                                           0                       0 
 
Other Operating Income                                   19,824                  50,984 
 
Administrative Expenses                               (152,785) 
 
                                                                   (88,167) 
 
Loss before Investment Activities                     (132,962)                (37,183) 
 
Fair Value of Receivables through Profit and Loss             0                       0 
 
Revaluation of loan                                           0                       0 
 
Provision against Amounts Receivable                          0                (18,690) 
 
Interest Income                                               0                  26,704 
 
Interest Payable at 7.1% on Preference Shares                 0               (163,450) 
 
(Loss) before Amortisation of Preference Shares       (132,962)               (192,619) 
 
Amortisation of Preference Shares                             0               (278,980) 
 
Profit/(Loss) before Taxation                         (132,962)               (471,599) 
 
Taxation Expense                                              0                       0 
 
Total Comprehensive Income attributable to Equity     (132,962)               (471,599) 
Holders of the Company 
 
STATEMENTS OF FINANCIAL POSITION (UNAUDITED) 
 
As at 30 June 2021 
 
                                                              Igraine plc 
 
                                                           As at                   As at 
 
                                                         30 June                 30 June 
 
                                                            2021                    2020 
 
                                                           £ GBP                   £ GBP 
 
Assets 
 
Non-current assets 
 
Property, plant and equipment                              1,048                     685 
 
Investments                                              615,113                 154,014 
 
                                                         616,161                 154,699 
 
Current assets 
 
Trade and other receivables                            1,450,284                 220,741 
 
Cash and cash equivalents                                 88,459                  11,610 
 
                                                       1,538,742                 232,351 
 
Total assets                                                                     387,050 
                                                     2,154,903 
 
Equity and liabilities 
 
Equity 
 
Issued share capital                                     587,166                  71,008 
 
Share Premium                                            166,268                       0 
 
Retained earnings                                      (811,673)             (4,441,482) 
 
                                                        (58,240)             (4,370,474) 
 
Non current liabilities 
 
Loans and borrowings                                      50,000               4,201,187 
 
Current liabilities 
 
Trade and other payables                               2,163,143                 556,337 
 
Total liabilities                                      2,213,143               4,757,524 
 
Total equity and liabilities                                                     387,050 
                                                   2,154,903 
 
THE DIRECTORS OF THE COMPANY TAKE RESPONSIBILITY FOR THE CONTENTS OF THIS 
ANNOUNCEMENT 
 
 
 
Enquiries 
 
Company: 
 
Martin Walton (Executive Director) 
Steve Winfield (Executive Director) 
 
AQSE Growth Market Corporate Adviser 
 
Peterhouse Capital Limited 
Guy Miller / Mark Anwyl 
Tel: +44 (0) 207 469 0930 
 
Media inquiries: 
 
Ramsay Smith, Media House International 
ramsay@mediahouse.co.uk: +44 (0) 7788414856 
 
 
 
END 
 
 

(END) Dow Jones Newswires

December 22, 2021 10:20 ET (15:20 GMT)

Igraine (AQSE:KING)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Igraine Charts.
Igraine (AQSE:KING)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Igraine Charts.